|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
43,990,000 |
Market
Cap: |
742.11(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$12.17 - $24.61 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
57,878 |
165,115 |
165,115 |
195,533 |
Total Sell Value |
$1,217,382 |
$3,085,988 |
$3,085,988 |
$4,069,195 |
Total People Sold |
2 |
2 |
2 |
3 |
Total Sell Transactions |
4 |
7 |
7 |
14 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mills Kenneth T. |
President and CEO |
|
2024-04-15 |
4 |
AS |
$18.19 |
$272,871 |
D/D |
(15,000) |
408,035 |
|
-7% |
|
Mills Kenneth T. |
President and CEO |
|
2024-04-15 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2024-03-19 |
4 |
OE |
$3.76 |
$75,354 |
D/D |
20,041 |
246,534 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2024-03-14 |
4 |
AS |
$21.86 |
$327,942 |
D/D |
(15,000) |
408,035 |
|
-23% |
|
Mills Kenneth T. |
President and CEO |
|
2024-03-14 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
Pakola Steve |
Chief Medical Officer |
|
2024-03-05 |
4 |
AS |
$28.36 |
$365,220 |
D/D |
(12,878) |
107,192 |
|
-32% |
|
Pakola Steve |
Chief Medical Officer |
|
2024-03-05 |
4 |
OE |
$22.25 |
$286,536 |
D/D |
12,878 |
120,070 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2024-02-14 |
4 |
AS |
$16.47 |
$251,349 |
D/D |
(15,000) |
408,035 |
|
0% |
|
Mills Kenneth T. |
President and CEO |
|
2024-02-14 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2024-01-16 |
4 |
AS |
$15.18 |
$682,992 |
D/D |
(45,000) |
408,035 |
|
10% |
|
Mills Kenneth T. |
President and CEO |
|
2024-01-16 |
4 |
OE |
$3.76 |
$169,200 |
D/D |
45,000 |
453,035 |
|
- |
|
Pakola Steve |
Chief Medical Officer |
|
2024-01-03 |
4 |
AS |
$17.39 |
$299,789 |
D/D |
(17,237) |
107,192 |
|
-3% |
|
Pakola Steve |
Chief Medical Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
32,051 |
124,429 |
|
- |
|
Pakola Steve |
Chief Medical Officer |
|
2024-01-02 |
4 |
D |
$17.95 |
$186,411 |
D/D |
(10,385) |
92,378 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
64,103 |
408,035 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2024-01-02 |
4 |
D |
$17.95 |
$203,858 |
D/D |
(11,357) |
343,932 |
|
- |
|
Simpson Curran |
Chief Oper. & Tech. Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
38,462 |
123,327 |
|
- |
|
Simpson Curran |
Chief Oper. & Tech. Officer |
|
2024-01-02 |
4 |
D |
$17.95 |
$145,754 |
D/D |
(8,120) |
84,865 |
|
- |
|
Christmas Patrick J. |
Chief Legal Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
34,615 |
115,759 |
|
- |
|
Christmas Patrick J. |
Chief Legal Officer |
|
2024-01-02 |
4 |
D |
$17.95 |
$141,679 |
D/D |
(7,893) |
81,144 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,026 |
226,493 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2024-01-02 |
4 |
D |
$17.95 |
$81,385 |
D/D |
(4,534) |
210,467 |
|
- |
|
Danos Olivier |
Chief Scientific Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
38,462 |
124,853 |
|
- |
|
Danos Olivier |
Chief Scientific Officer |
|
2024-01-02 |
4 |
D |
$17.95 |
$150,960 |
D/D |
(8,410) |
86,391 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2023-12-19 |
4 |
AS |
$19.69 |
$885,825 |
D/D |
(45,000) |
355,289 |
|
-17% |
|
404 Records found
|
|
Page 1 of 17 |
|
|